FindTrial
Sign In

To compare two types of injectable iron therapies ( Ferric carboxymaltose and iron sucrose) for treatment of anemia (low Hemoglobin) due to heavy menstrual bleeding

To compare the efficacy of intravenous ferric carboxymaltose versus iron sucrose in the management of anemia of abnormal uterine bleeding

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/09/006224
Enrollment
60
Registered
2015-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- anemic patients

Interventions

Intervention1: Injection Ferric carboxymaltose: Hb deficit was clculated according to Ganzonis formula and Inj carboxymaltose was given in dose of 1000mg intravenously in 100ml saline over 15-20 min C

Sponsors

Dr Alka Kriplani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hb less than 11 Intolerance to oral Iron Not trying for conception PBAC more than 100

Exclusion criteria

Exclusion criteria: Anaemia due to any other cause Disorders of erythropoiesis Malignancies Deranged Liver and/or kidney functions Recent blood transfusion or parenteral Iron therapy

Design outcomes

Secondary

MeasureTime frame
Proportion of patients achieving normalisation of Hemoglobin Rise in Serum Ferritin and Serum Iron Improvement in fatigue levels Side effects of the drugTimepoint: 6 weeks, 12 weeks—

Primary

MeasureTime frame
Rise in Hemoglobin Rate of rise in HemoglobinTimepoint: 1 week, 2 weeks, 4 weeks, 6 weeks, 12 weeks—

Countries

India

Contacts

Public ContactDr Alka Kriplani

AIIMS, New Delhi

kriplanialka@gmail.com011-26593221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 4, 2026